256935-75-8 Usage
Uses
Used in Pharmaceutical Industry:
Ethyl imidazo[1,5-a]pyridine-6-carboxylate is utilized as a key intermediate for the synthesis of various drugs and pharmaceuticals. Its unique structure and reactivity contribute to the development of new therapeutic agents.
Used in Drug Development for Cancer Treatment:
Ethyl imidazo[1,5-a]pyridine-6-carboxylate is employed as a precursor in the development of new drugs for the treatment of cancer. Its complex structure allows for the creation of molecules with potential anti-cancer properties.
Used in Drug Development for Neurological Disorders:
ethyl imidazo[1,5-a]pyridine-6-carboxylate is also used as a building block in the synthesis of drugs intended for the treatment of neurological disorders, leveraging its structural complexity to target specific neurological pathways.
Used in Drug Development for Infectious Diseases:
Ethyl imidazo[1,5-a]pyridine-6-carboxylate plays a role in the development of new drugs to combat infectious diseases, with its unique structure potentially leading to the creation of effective antimicrobial agents.
Check Digit Verification of cas no
The CAS Registry Mumber 256935-75-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,6,9,3 and 5 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 256935-75:
(8*2)+(7*5)+(6*6)+(5*9)+(4*3)+(3*5)+(2*7)+(1*5)=178
178 % 10 = 8
So 256935-75-8 is a valid CAS Registry Number.
256935-75-8Relevant academic research and scientific papers
SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
-
, (2013/07/19)
Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
CEPHALOSPORIN HAVING CATECHOL GROUP
-
, (2011/07/30)
The present invention provides Cephem compounds which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria as follows: A compound of the formula: wherein, X is N, CH or C-Cl; T is S or the like; A and G are lower alkylene or the like; B is a single bond or the like; D is a single bond, -NR7-, -CO-, -CO-NR7-, -NR7-CO-, -NR7-CO-NR7-, or the like; E is optionally substituted lower alkylene; F is a single bond or optionally substituted phenylene; R3, R4, R5 and R6 each is independently hydrogen, halogene, nitrile, or the like; or an ester, a compound protected at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.
